Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced the granting of stock options to three new employees. The Compensation Committee approved non-qualified stock options to purchase 101,000 shares of common stock under the company's 2022 Inducement Stock Incentive Plan. These options, effective October 1, 2024, have an exercise price of $0.75 per share, matching the closing price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employment.
Xilio Therapeutics (Nasdaq: XLO), una azienda biotecnologica in fase clinica focalizzata sulle terapie immuno-oncologiche attivate dai tumori, ha annunciato l'assegnazione di opzioni su azioni a tre nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni su azioni non qualificate per l'acquisto di 101.000 azioni ordinarie nell'ambito del Piano di Incentivazione delle Azioni per Induzione 2022 della società. Queste opzioni, efficaci dal 1° ottobre 2024, hanno un prezzo di esercizio di $0,75 per azione, corrispondente al prezzo di chiusura in quella data. Le opzioni hanno un termine di dieci anni e matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura in rate mensili uguali nei tre anni successivi. Questa concessione è in linea con la Regola di Quotazione Nasdaq 5635(c)(4) per gli incentivi materiali a nuovi impieghi.
Xilio Therapeutics (Nasdaq: XLO), una empresa biotecnológica en etapa clínica centrada en terapias de inmuno-oncología activadas por tumores, ha anunciado la concesión de opciones sobre acciones a tres nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no calificadas para la compra de 101,000 acciones ordinarias bajo el Plan de Incentivo de Acciones por Inducción 2022 de la compañía. Estas opciones, efectivas a partir del 1 de octubre de 2024, tienen un precio de ejercicio de $0.75 por acción, coincidiendo con el precio de cierre en esa fecha. Las opciones tienen un plazo de diez años y se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el 75% restante consolidándose en cuotas mensuales iguales durante los tres años siguientes. Esta concesión se alinea con la Regla de Cotización de Nasdaq 5635(c)(4) para incentivos materiales a nuevos empleos.
Xilio Therapeutics (Nasdaq: XLO)는 임상 단계의 생명공학 회사로서 종양 활성화 면역 종양학 치료에 중점을 두고 있으며, 3명의 신규 직원에게 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회사의 2022 유도 주식 인센티브 계획에 따라 101,000주의 보통주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다. 이 옵션은 2024년 10월 1일부터 유효하며, 주당 $0.75의 행사 가격으로, 해당 날짜의 종가와 일치합니다. 옵션의 유효 기간은 10년이며 4년 동안 분할되어 가득 차게 되며, 1년 후에 25%가 가득 차고 나머지 75%는 이후 3년에 걸쳐 매달 동일한 할부로 가득 차게 됩니다. 이 부여는 신규 고용에 대한 유인물로서 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise biotechnologique en phase clinique spécialisée dans les thérapies immuno-oncologiques activées par les tumeurs, a annoncé l'octroi de options d'actions à trois nouveaux employés. Le Comité de rémunération a approuvé des options d'actions non qualifiées pour l'achat de 101 000 actions ordinaires dans le cadre du Plan d'incitation aux actions 2022 de l'entreprise. Ces options, effectives à partir du 1er octobre 2024, ont un prix d'exercice de 0,75 $ par action, correspondant au prix de clôture de ce jour-là. Les options ont une durée de dix ans et seront acquises sur quatre ans, avec 25 % acquises après un an et le reste de 75 % acquis en versements mensuels égaux au cours des trois années suivantes. Cet octroi est conforme à la règle de cotation Nasdaq 5635(c)(4) relative aux incitations matérielles pour un nouvel emploi.
Xilio Therapeutics (Nasdaq: XLO), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf tumorfokussierte Immunonkologie-Therapien spezialisiert hat, hat die Gewährung von Aktienoptionen an drei neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 101.000 Stammaktien im Rahmen des Aktienoptionsplans für Anwerbung 2022 des Unternehmens. Diese Optionen treten am 1. Oktober 2024 in Kraft und haben einen Ausübungspreis von $0,75 pro Aktie, der dem Schlusskurs an diesem Tag entspricht. Die Optionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre vollständig fällig, wobei 25% nach einem Jahr und die verbleibenden 75% in gleichen monatlichen Raten über die folgenden drei Jahre fällig sind. Diese Gewährung entspricht der Nasdaq-Listing-Regel 5635(c)(4) für Anreizzahlungen für neue Beschäftigungsverhältnisse.
- Xilio Therapeutics is attracting new talent with stock option incentives
- The company maintains a stock incentive plan to align employee interests with shareholders
- The low stock price of $0.75 per share may indicate financial challenges or market skepticism
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock options to purchase an aggregate of 101,000 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as inducements material to the individuals entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
How many shares of Xilio Therapeutics (XLO) stock options were granted to new employees?
What is the exercise price of the stock options granted by Xilio Therapeutics (XLO) on October 1, 2024?
What is the vesting schedule for the stock options granted by Xilio Therapeutics (XLO)?
Under which plan were the Xilio Therapeutics (XLO) stock options granted?
